Valuation: Sprint Bioscience AB

Market Cap 407M 42.25M 36.96M 34.09M 31.48M 59.74M 4.03B 60.74M 160M 1.99B 159M 155M 6.82B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 407M 42.25M 36.96M 34.09M 31.48M 59.74M 4.03B 60.74M 160M 1.99B 159M 155M 6.82B EV / Sales 2026 *
4.8x
EV / Sales 2027 * 2.63x
Free-Float
64.78%
Yield 2026 *
-
Yield 2027 * -
1 day-1.30%
1 week+2.97%
Current month-7.97%
1 month-7.52%
3 months+1.60%
6 months+154.00%
Current year+159.18%
1 week 3.55
Extreme 3.55
3.99
1 month 3.55
Extreme 3.55
4.59
Current year 1.36
Extreme 1.355
4.59
1 year 0.48
Extreme 0.477
4.59
3 years 0.36
Extreme 0.36
4.59
5 years 0.36
Extreme 0.36
9.36
10 years 0.36
Extreme 0.36
41.9
Manager TitleAgeSince
Chief Executive Officer 42 01/10/2023
Chief Tech/Sci/R&D Officer 55 01/01/2009
Director of Finance/CFO 55 04/05/2026
Director TitleAgeSince
Chairman 70 01/01/2010
Director/Board Member 50 01/01/2019
Chairman 58 01/01/2021
Change 5-day change 1-year change 3-year change Capi.($)
-1.30%+2.97%+632.69%+621.59% 42.25M
+1.84%-0.66%+59.82%+94.48% 54.88B
-0.84%-6.89%+55.31%+127.53% 54.63B
-4.58%-1.26%+8.10%+425.23% 25.06B
-0.31%-2.49%-17.48%-16.36% 23.14B
-1.69%-1.27%+39.51%-8.30% 19.87B
+1.18%+3.17%+37.43%-27.12% 17.55B
-6.84%+2.18%+195.12%+364.56% 16.5B
-2.42%-3.72%+47.02%+635.77% 15.75B
-1.88%-0.29%+21.48%+186.15% 14.2B
Average -1.73%-0.77%+107.90%+240.35% 24.16B
Weighted average by Cap. -1.11%-1.45%+48.99%+167.57%

Financials

2026 *2027 *
Net sales 84.8M 8.8M 7.69M 7.1M 6.56M 12.44M 839M 12.65M 33.3M 413M 33.03M 32.31M 1.42B 155M 16.08M 14.06M 12.97M 11.98M 22.73M 1.53B 23.12M 60.87M 755M 60.37M 59.06M 2.6B
Net income - -
Net Debt - -
Logo Sprint Bioscience AB
Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Company’s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.
Employees
30
Date Price Change Volume
14/07/26 SEK 3.810 -1.30% 217,924
10/07/26 SEK 3.860 +1.58% 175,472
09/07/26 SEK 3.800 0.00% 272,825
08/07/26 SEK 3.800 -2.06% 148,749
07/07/26 SEK 3.880 +4.86% 319,257

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SPRINT Stock